Skip to main content
Atrás
Watch Compare

BioXcel Therapeutics, Inc.

Calidad de datos: 100%
BTAI
Nasdaq Manufacturing Chemicals
$1.06
▼ $0.02 (-1.85%)
Cap. Mercado: 29.24 M
Precio
$1.08
Cap. Mercado
29.24 M
Rango del Día
—
Rango de 52 Semanas
—
Volumen
—
Apertura —
Promedio 50D / 200D
—
Promedio 50D / 200D
—

Quick Summary

Puntos Clave

Negative free cash flow of -57.62 M
Capital efficient — spends only 0.00% of revenue on capex

Crecimiento

Revenue Growth (5Y)
N/A
Revenue (1Y)-71.67%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Calidad

Return on Equity
N/A
ROICN/A
Net Margin-10887.38%
Op. Margin-7859.97%

Seguridad

Debt / Equity
N/A
Current Ratio1.17
Interest Coverage-3.29

Valoración

PE (TTM)
-0.42
Above sector avg (-1.48)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Manufacturing (1366 pares)
Métrica Acción Mediana del Sector
P/E -0.4 -1.5
P/B — 1.6
ROE % — -53.5
Net Margin % -10887.4 -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3

Precio Objetivo de Analistas

4 analistas
Hold
Actual
$1.06
+1220.8%
Objetivo
$14.00
$1.00
$8.50
$38.00
Pronóstico
P/E Futuro -0.64
EPS Futuro -$1.65
Ingresos Est. 18.93 M

Estimaciones de Ganancias

Período EPS Est. Ingresos Est. Analistas
FY2027 -$1.65
-$2.38 – -$1.12
 18.93 M 3
FY2026 -$1.96
-$3.17 – -$1.18
 1.87 M 3

Sorpresas de Ganancias

Últimos 4 trimestres
Trimestre EPS Est. EPS Real Sorpresa
Q42025 -$0.64 N/A —
Q32025 -$1.34 -$2.16 -61.5%
Q22025 -$1.56 -$2.45 -56.7%
Q12025 -$3.04 -$1.50 +50.7%

All Fundamental Metrics
Growth
Revenue Growth (1Y) -71.67% Revenue Growth (3Y) -31.79%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 642,000.0 Net Income (TTM) -69.90 M
ROE N/A ROA -198.06%
Gross Margin N/A Operating Margin -7859.97%
Net Margin -10887.38% Free Cash Flow (TTM) -57.62 M
ROIC N/A FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 1.17
Interest Coverage -3.29 Asset Turnover 0.02
Working Capital 6.60 M Tangible Book Value -88.92 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0.42 Forward P/E N/A
P/B Ratio N/A P/S Ratio 45.55
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -197.04%
Market Cap 29.24 M Enterprise Value 102.19 M
Per Share
EPS (Diluted TTM) -5.73 Revenue / Share 0.02
FCF / Share -2.13 OCF / Share -2.13
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 0.00% FCF Conversion 82.43%
SBC-Adj. FCF -61.80 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 642,000.0 2.27 M 1.38 M 375,000.0 —
Net Income -69.90 M -59.60 M -179.05 M -165.76 M -106.93 M
EPS (Diluted) -5.73 -23.51 -6.15 -5.92 -4.05
Gross Profit — — — — —
Operating Income -50.46 M -67.25 M -171.78 M -159.65 M -106.94 M
EBITDA — — — — —
R&D Expenses 30.25 M 30.44 M 84.33 M 91.24 M 52.71 M
SG&A Expenses 20.49 M 34.49 M 83.41 M 68.76 M —
D&A — — — — 297,000.0
Interest Expense 15.33 M 14.66 M 13.31 M 8.21 M 40,000.0
Income Tax 0.0 0.0 — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 44.92 M 38.34 M 73.70 M 205.85 M 239.44 M
Total Liabilities 140.38 M 131.44 M 130.21 M 129.08 M 17.77 M
Shareholders' Equity -95.46 M -93.10 M -56.51 M 76.78 M 221.67 M
Total Debt 109.59 M 102.51 M 100.60 M 93.05 M —
Cash & Equivalents 28.42 M 29.85 M 65.22 M 193.73 M 232.97 M
Current Assets 44.69 M 37.39 M 72.14 M 202.87 M 236.81 M
Current Liabilities 53.93 M 22.23 M 27.27 M 32.90 M 16.67 M